T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Oct 2021
Historique:
received: 24 02 2021
revised: 11 06 2021
accepted: 26 06 2021
pubmed: 13 7 2021
medline: 10 8 2021
entrez: 12 7 2021
Statut: ppublish

Résumé

Tuberculosis, a cost and life threatening disease, was being subjected for improving vaccine strategies beyond BCG. Thus, a novel particulate delivery system using alginate-coated chitosan nanoparticles including PPE17 protein and CpG were administered through intranasal (IN) and subcutaneous (SC) routes. The encapsulated nanoparticles were first characterized for size, surface charge, encapsulation efficiency and in vitro release of PPE17 antigen. The nanoparticles were then administered intranasal and subcutaneously to evaluate the induction of systemic and/or mucosal immune responses in mice. According to our result, the mean size of nanoparticles was measured about 427 nm, and exhibited a negative zeta potential of -37 mV. Following subcutaneous and intranasal administration, the results from cytokines assay showed that an increasing in the level of IFN-γ, and adversely a decrease in the level of IL-4 (presumptive Th1 biased immune response) was happened and also a notable elicitation in IL-17 cytokine was observed. In conclusion, our study demonstrated that alginate-coated chitosan nanoparticles showed to be an effective way to improve BCG efficiency as booster strategy for subcutaneous vaccine, and also can induce strong immune responses as prime strategy through intranasal vaccination.

Identifiants

pubmed: 34252419
pii: S0024-3205(21)00792-X
doi: 10.1016/j.lfs.2021.119806
pii:
doi:

Substances chimiques

Alginates 0
Antigens, Bacterial 0
Drug Carriers 0
Rv1168c protein, Mycobacterium tuberculosis 0
Tuberculosis Vaccines 0
Chitosan 9012-76-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119806

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Adel Najafi (A)

Clinical Microbiology Laboratory, Fatemieh Hospital, Hamedan University of Medical Science, Hamedan, Iran.

Kiarash Ghazvini (K)

Department of Microbiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.

Mojtaba Sankian (M)

Immunology Research Center, Bu Ali Research Institute, Mashhad University of Medical Science, Mashhad, Iran.

Leila Gholami (L)

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Science, Mashhad, Iran.

Yousef Amini (Y)

Department of Microbiology, Faculty of Medicine, Zahedan University of Medical Science, Zahedan, Iran.

Sirwan Zare (S)

Immunology Research Center, Bu Ali Research Institute, Mashhad University of Medical Science, Mashhad, Iran.

Farzad Khademi (F)

Department of Microbiology, School of Medicine, Ardabil University of Medical Science, Ardabil, Iran.

Mohsen Tafaghodi (M)

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Science, Mashhad, Iran. Electronic address: tafaghodim@mums.ac.ir.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH